Sunday 26 May 2024

12:00-13:00 CEST

Gedeon Richter

Benchmarking osteoanabolic treatment for the high-risk patient

Room Endoume 1+2

Chair: Serge Ferrari, Marie-Hélène Lafage-Proust

12:00 Welcome and introduction

12:05 The significance of bone remodelling for bone health – Lothar Seefried, Germany

12:25 Translating teriparatide biological effects into clinical efficacy – Serge Ferrari, Switzerland

12:45 Panel disucssion and Q&A

Sunday 26 May 2024

15:00-16:00 CEST

Inozyme Pharma

The ENPP1 protein – an important regulator of skeletal mineralization

Room: Endoume 1+2

Speaker: Lothar Seefried, Orthopedic Center  for Musculoskeletal Research,  Wuerzburg, Germany

Objectives:

1. The ENPP1 protein and skeletal mineralization 
2. Musculoskeletal diseases associated with ENPP1 Deficiency
3. Bone microarchitecture and bone mass abnormalities observed in conditions of ENPP1 Deficiency

Monday 27 May 2024

15:00-16:00 CEST

Kyowa Kirin

Optimising the care of adults with XLH

Room: Callelongue

Chair: Professor Martine Cohen-Solal

15:00 Welcome and introduction
Professor Martine Cohen-Solal
15:05 Practical considerations when monitoring treatment response in adults with XLH
Professor Martine Cohen-Solal
15:10 Treatment of adults with XLH: Latest insights from an early‑access programme
Professor Richard Keen
15:30 Real-world case studies on the management of adults with XLH
Both Speakers
15:50 Panel discussion and Q&A
Both speakers
16:00 Summary and Meeting close
Professor Martine Cohen-Solal

Monday 27 May 2024

15:00-16:00 CEST

Bruker BioSpin GmbH & Co. KG
Biospace Lab

Room: Endoume 1+2

30 minutes talk

Bruker BioSpin GmbH & Co. KG
Speaker Phil Salmon, Bruker BioSpin, Kontich, Belgium

Barcodes and spatial maps of change: 4-dimensional analysis of bone and lung architecture from microCT

7 minutes talk

Biospace Lab

Speaker Joelle Tchicaya, Biospace Lab, Nesles la vallée, France

The valuable assets of rel-time bioluminescence and nir I fluorescence imaging